← Human Trials & Peer-Reviewed Studies
Effects of growth hormone (GH) replacement on bone metabolism and mineral density in adult onset of GH deficiency: results of a double-blind placebo-controlled study with open follow-up.
Plain-language guide to PMID 9100553 (1997): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 20 patients.
Key Facts
- PMID
- 9100553
- Journal
- European journal of endocrinology
- Year
- 1997
- Study type
- Randomized Controlled Trial
- Authors
- Finkenstedt G et al. (5 authors)
- DOI
- 10.1530/eje.0.1360282
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.
It is known that GH stimulates bone turnover and that GH-deficient adults have a lower bone mass than healthy controls.
BMD did not change during this period of time.
Who Took Part
The abstract describes 20 patients taking part.
PubMed indexes the participants as adults and middle-aged adults, both men and women.
Eighteen patients, fourteen men and four women, with a mean age of 44 years with adult onset GH deficiency were evaluated in the study.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the patients and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.
What Was Measured
The subject headings attached to it are Absorptiometry, Photon, Bone Density, Femur, Human Growth Hormone, Recombinant Proteins and Spine.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 20 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1997 (European journal of endocrinology), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.